Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04126018
Other study ID # 19-549
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 23, 2019
Est. completion date June 30, 2026

Study information

Verified date December 2023
Source The Cleveland Clinic
Contact Deborah Kwon, M. D.
Phone 216-444-8526
Email kwond@ccf.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of the study is to compare the various 2D and 3D methods of valvular heart disease quantification (Doppler, PISA, VCA, volumetric method) and strain with cardiac magnetic resonance (CMR) measurements of left and right ventricular systolic function strain and myocardial fibrosis assessment.


Description:

The objective of this study is to compare the accuracy of 3D TTE to 2D TTE in assessing the severity of valvular heart disease in patients with aortic stenosis, aortic regurgitation, and mitral valve regurgitation by comparing this to the reference standard of cardiac magnetic resonance (CMR) in subjects with different etiologies and mechanisms of valvular lesions and to the integrative method of valvular lesion grading as recommended by inter-societal guidelines. Another objective is to assess prevalence of focal and diffuse myocardial fibrosis as assessed by CMR in patients with aortic stenosis, aortic regurgitation and mitral regurgitation. In addition, the investigators aim to determine whether severity of myocardial fibrosis predicts onset of symptoms, referral for valve surgery and adverse ventricular remodeling. The investigators also aim to look at patients who will be undergoing CRT implant to predict their response to therapy. At baseline, the Rapid Assessment of Physical Activity questionnaire and the Kansas City Cardiomyopathy Questionnaire will be completed. A 6-12 month follow-up is required and will include an abbreviated non-contrast research cardiac MRI and subject questionnaires. Other follow-up will include using electronic medical records and the Social Security Death Index database for outcomes such as death, hospitalization for heart failure, mitral or aortic valve interventions and cardiovascular death. Select patients will be asked to undergo a supine bicycle exercise stress MRI at enrollment. Approximately 40 subjects will be included in this substudy. Additional exclusion criteria for this substudy: - Unable to pedal a supine bicycle - Require supplemental oxygen During the exercise stress MRI, patients will be asked to cycle on a supine bike that will be mounted on the MRI platform. During this test, a caregiver will be present. An electrocardiogram (ECG) will be used to obtain tracings of cardiac activity. Respirations, blood pressure, and heart rate are also monitored during exercise. The test is continued until peak exercise level or target heart rate is achieved. As soon as the exercise portion is complete, MRI images will be acquired. When the test is complete, patients will be monitored until ECG, heart rate, and breathing have returned to baseline. Patients will be assessed for symptoms such as chest pain, dyspnea, leg pain, dizziness, or fatigue and may be given medications or instructed to stop the test early as necessary.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date June 30, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Age 18-90 years of age - Suspected moderate or severe MR,AR or AS on the basis of prior known clinical history or clinical exam. - Suspected CRT "non-responder" with an implanted MRI compatible CRT device and reduced ejection fraction Exclusion Criteria: - Acute traumatic cardiac injury - Aortic dissection or aortic root rupture - Congenital heart diseases such as patent ductus arteriosus, coarctation of aorta, ASD and VSD - Presence of A-V fistula or intracardiac shunts - Any contraindications to CMR - Moderate or severe dysfunction in multiple valves - Patients with significant claustrophobia

Study Design


Intervention

Diagnostic Test:
MRI with strain measurement
CMR measurements of left and right ventricular systolic function strain and myocardial fibrosis
Echocardiography
Doppler, PISA, VCA, volumetric method as performed during echocardiography

Locations

Country Name City State
United States Cleveland Clinic Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
The Cleveland Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in MRI Quantified LVEDVi 10% Change from Baseline - units of measure cc/m2 6 months
Primary Change in MRI Quantified LVESVi 15% Change from Baseline - units of measure cc/m2 6 months
Primary Change in MRI Quantified LV Strain 5% Change from Baseline 6 months
Primary Change in MRI LVEF 5% Change from Baseline 6 Months
Primary Change in Kansas City Cardiomyopathy Questionnaire Answers Change in quality of life related to heart failure symptoms. 6 Months
Primary Change in Physical Activity Questionnaire Answers Change in physical activity level due to heart failure symptoms. 6 Months
Primary All-cause mortality number of patients expired 6 Months
Primary Development of class I or IIa indication for valve surgery The recommended indications for surgery include: development of symptoms, LV dysfunction (LV end-systolic diameter =45 mm or LV ejection fraction =60%), and new onset of atrial fibrillation or pulmonary hypertension (systolic pulmonary artery pressure >50 mm Hg at rest). 6 Months
Secondary Accuracy of echocardiography as compared with MRI Comparison of MRI measurements based on standard of care echocardiography. 6 Months
See also
  Status Clinical Trial Phase
Recruiting NCT04310046 - Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial N/A
Completed NCT03332745 - Mechanism of Decompensation Evaluation - Aortic Stenosis
Recruiting NCT06008080 - Post-Market Clinical Follow Up Study With Navitor Valve
Recruiting NCT06055751 - Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
Active, not recruiting NCT04815785 - Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis N/A
Terminated NCT02202434 - Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement N/A
Recruiting NCT03029026 - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Active, not recruiting NCT02903420 - A Clinical Trial of Transcatheter Aortic Valves in Dialysis Patients (Japan) N/A
Completed NCT02629328 - CardioCel Tri-leaflet Repair Study N/A
Completed NCT02306226 - Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry
Completed NCT01676727 - ADVANCE Direct Aortic Study
Withdrawn NCT01648309 - Neuropsychological Testing in Patients Undergoing Transvascular Aortic Valve Implantation N/A
Completed NCT01422044 - Risk Prediction in Aortic Stenosis N/A
Withdrawn NCT00774657 - Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography N/A
Terminated NCT00535899 - Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS) N/A
Terminated NCT05070130 - OpSens PRIME CLASS
Completed NCT03314857 - China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population N/A
Completed NCT04157920 - Impact of Predilatation Between Self-expanding Valves N/A
Enrolling by invitation NCT06212050 - Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
Recruiting NCT05893082 - Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR N/A